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ABSTRACT
The aim of this study was to elucidate the roles of the b1- and the
b2-adrenoceptors in thermogenesis and lipid utilization in obesity.
The b1-adrenoceptor study was performed in 9 obese and 10 lean men
and consisted of 4 30-min periods during which subjects received
consecutive infusions of 0, 3, 6, and 9 mg/kg fat-free mass (FFM)zmin
dobutamine. Energy expenditure, lipid oxidation, and plasma non-
esterified fatty acids and glycerol concentrations increased similarly
in both groups during b1-adrenergic stimulation. The b2-adrenoceptor
study was performed in 10 obese and 11 lean men and involved 3
45-min periods during which 0, 50, and 100 ng/kg FFMzmin salbu-
tamol were given in combination 1.2 mg/kg FFMzmin atenolol (bolus,
50 mg/kg FFM). During b2-adrenergic stimulation, the increases in
energy expenditure and plasma nonesterified fatty acids and glycerol
concentrations were reduced in the obese group. Furthermore, lipid
oxidation significantly increased in the normal weight group, but
remained similar in the overweight group. In conclusion, these data
suggest that b1-adrenoceptor-mediated metabolic processes are sim-
ilar in both groups, but b2-adrenoceptor-mediated increases in ther-
mogenesis and lipid utilization are impaired in the obese. (J Clin
Endocrinol Metab 86: 2191–2199, 2001)
THE SYMPATHETIC nervous system plays an importantrole in the regulation of thermogenesis and lipid uti-
lization. Studies in which the endogenous catecholamines
norepinephrine (1, 2) and epinephrine (3–5) (both nonselec-
tive a- and b-adrenoceptor agonists) are infused show sig-
nificant increases in energy expenditure, lipid oxidation, and
lipolysis. The roles of the individual adrenoceptor subtypes
in thermogenesis have also been studied. a-Adrenergic stim-
ulation does not affect whole body thermogenesis (3, 6),
whereas nonselective b-adrenergic stimulation with isopren-
aline significantly increases energy expenditure and lipid
utilization (7). During only b1-adrenergic stimulation with
dobutamine (8, 9) or only b2-adrenergic stimulation with
salbutamol (6) or terbutaline (10), energy expenditure, lipid
oxidation, and lipolysis increase as well. In rats, b3-adren-
ergic stimulation leads to significant increases in energy ex-
penditure and lipid utilization (11, 12). However, the rat
b3-adrenoceptor differs pharmacologically from the human
b3-adrenoceptor (13, 14), and consequently, the specific b3-
adrenoceptor agonists used in rats are only weak agonists in
humans. Until now, no highly selective b3-adrenoceptor ag-
onist or antagonist has been available for administration in
humans.
Obese subjects may show an impaired response of ther-
mogenesis during norepinephrine infusion (15, 16), but re-
sponses similar to those in lean subjects are also frequently
found during norepinephrine (17, 18), epinephrine (5, 19),
and isoprenaline (7) infusion. Others only found an impaired
thermogenic response when very obese men were compared
with very lean men (20) or only during overfeeding (18).
More evident are the differences in lipid utilization between
obese and lean subjects. During epinephrine (5, 19) or iso-
prenaline (7) infusion, the increase in lipid oxidation is re-
duced in overweight men. Furthermore, their increases in
plasma nonesterified fatty acids (NEFA) and glycerol con-
centrations are impaired during epinephrine (5, 21) or iso-
prenaline (7) infusion. Only Katzeff et al. (17) reported an
opposite finding, e.g. that the increases in plasma glycerol
and NEFA concentrations in response to norepinephrine in-
fusion were proportional to the total fat mass of each indi-
vidual and therefore were greater in the obese. Until now, it
has been unclear which b-adrenoceptor subtype is respon-
sible for the impaired responses of thermogenesis and lipid
utilization.
The aim of the present studies was to elucidate the roles
of b1- and b2-adrenoceptors in thermogenesis, lipid oxida-
tion, and lipolysis in obese and lean men.
Subjects and Methods
Subjects
Fourteen obese and 15 lean male volunteers participated in these
studies. Six obese and 6 lean men participated in both studies within a
time frame of 9 6 2 months. The physical characteristics of the subjects,
grouped per study, are summarized in Table 1. All subjects were in good
health as assessed by medical history and physical examination and
were weight stable for at least 6 months. Furthermore, both obese and
lean subjects spent no more than 2 h a week in organized sports activities.
The study protocols were reviewed and approved by the ethics com-
mittee of Maastricht University, and all subjects gave informed consent
before participating in the tests.
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Experimental design
Subjects were studied in the morning after an overnight fast. They
came to the laboratory by car or bus to minimize the amount of physical
activity before the test. On arrival, a cannula was inserted into a forearm
vein of each arm. One cannula was used for the infusion of drugs, and
one cannula was used for the sampling of blood. Next, ventilated hood
measurements were started with the subject in supine position and
continued for the remainder of the experiment. At the end of each study
period, a blood sample was taken. Room temperature was kept at
21223 C.
The b1-adrenoceptor study consisted of four study periods. After a
30-min baseline measurement, subjects received consecutive infusions of
3, 6, and 9 mg/kg fat-free mass (FFM)zmin dobutamine (Dobax, Byk,
Zwanenburg, The Netherlands), each dose for 30 min.
The b2-adrenoceptor study consisted of three study periods. At the
start of the experiment, subjects received a priming dose of 50 mg/kg
FFM atenolol (b1-adrenoceptor antagonist, Tenormin, Zeneca Pharma-
ceuticals, Ridderkerk, The Netherlands) in 5 min, after which a contin-
uous infusion of 1.2 mg/kg FFMzmin atenolol was started for the re-
mainder of the experiment. After a 45 min baseline measurement,
subjects additionally received consecutive infusions of 50 and 100 ng/kg
FFMzmin salbutamol (Ventolin, GlaxoWellcome, Zeist, The Nether-
lands), each infusion for 45 min.
Clinical methods
Body density was determined by hydrostatic weighing with simul-
taneous lung volume measurement (Volugraph 2000, Mijnhardt, Bun-
nik, The Netherlands). Body composition was calculated according to
the equation of Siri (22).
Whole body energy expenditure and respiratory exchange ratio
(RER) were measured by indirect calorimetry, using an open-circuit
ventilated hood system. In the b1-adrenoceptor study, a homemade
system was used (23). The volume of air drawn through the hood was
measured by a dry gas meter (Schlumberger, Dordrecht, The Nether-
lands), and the composition of the in-flowing and out-flowing air was
analyzed by a paramagnetic O2 analyzer (Servomex, Crowborough, UK)
and an infrared CO2 analyzer (Hartmann and Braun, Frankfurt, Ger-
many). In the b2-adrenoceptor study, energy expenditure and RER were
measured by an Oxycon (Mijnhardt, Bunnik, The Netherlands). The
airflow rate and the O2 and CO2 concentrations of the in- and out-
flowing air were used to compute O2 consumption and CO2 production
on-line through an automatic acquisition system connected to a personal
computer. The coefficient of variation for O2 consumption was 2.4% for
the homemade system and 2.5% for the Oxycon; the coefficient of vari-
ation for CO2 production was 3.1% for the homemade system and 2.0%
for the Oxycon. Energy expenditure was calculated according to the
formula proposed by Weir (24). Energy expenditure and RER values
were averaged over the last 10 min of each 30-min (b1) or 45-min (b2)
period during which steady state occurred. During the b2-adrenoceptor
study, subjects collected their urine for nitrogen determination over a
12-h period before arriving at the laboratory. Nitrogen excretion was
used to estimate protein oxidation at baseline and was assumed to be
constant during the remainder of the test. For subjects who only par-
ticipated in the b1-adrenoceptor study, the mean nitrogen excretion rate
for the corresponding group in the b2-adrenoceptor study was used.
After correction for protein oxidation, carbohydrate and lipid oxidation
rates were calculated from O2 consumption and CO2 production as
described by Ferrannini (25).
Heart rate was monitored continuously by conventional electrocar-
diography, and the mean value over the last 10 min of each measuring
period was used for further analysis. Blood pressure was measured by
an automated blood pressure device (Tonoprint, Speidel & Keller, Jung-
ingen, Germany) during the last 10 min of each 30-min (b1) or 45-min
(b2) interval. The means of four measurements per interval were used
for further analysis.
Analytical methods
Blood samples for the determination of NEFA, glycerol, glucose,
lactate, and insulin were preserved in sodium ethylenediamine tetraac-
etate; samples for potassium were preserved in heparin; and those for
dobutamine, salbutamol, norepinephrine, and epinephrine were pre-
served in heparin plus glutathione (1.5%, wt/vol). Blood samples were
immediately centrifuged for 10 min at 800 3 g at 4 C. Plasma was
transferred into microtest tubes, rapidly frozen in liquid nitrogen, and
stored at 270 C until further analysis.
The plasma NEFA concentration was measured with a NEFA C kit
(99475409, WAKO, Neuss, Germany), the plasma glycerol concentration
was measured with a glycerol kit (148270, Roche, Mannheim, Germany),
the plasma glucose concentration was measured with a glucose kit
(Unimate 5, 0736724, Roche, Basel, Switzerland), and the plasma lactate
concentration was measured by the method of Gutmann and Wahlefeld
(26), all on a Cobas-Fara centrifugal analyzer (Roche, Basel, Switzer-
land). The plasma insulin concentration was determined with a double
antibody RIA (Insulin RIA 100, Pharmacia, Uppsala, Sweden), and the
plasma potassium concentration was determined by an ion-selective
electrode (Salm & Kipp, Breukelen, The Netherlands). Plasma dobut-
amine, norepinephrine, and epinephrine levels were determined by high
performance liquid chromatography according to the method described
by Alberts et al. (27). Plasma salbutamol concentrations were measured
by an in-house method (Analytico Medinet, Breda, The Netherlands)
Salbutamol was first extracted from its matrix by means of a solid phase
extraction procedure. After derivatization with BSTFA (trimethylsilyl-
trifluoracetamide), its concentration was determined using a capillary
gas chromatography-mass spectrometry method. Quantification was
performed by monitoring the ion fragments at 456 m/z for salbutamol
and 459 m/z for the internal standard D3-salbutamol and calculation of
peak height ratio analyte/internal standard amounts. The limit of quan-
tification in plasma was 1.0 nmol/L, based on a 1-mL sample volume.
The calibration range was between 1 and 40 nmol/L. Standard samples
with known concentrations were included in each run for quality
control.
Data analysis
All data are presented as the mean 6 sem. Data for energy expen-
diture were adjusted for FFM for group comparison (28).
The effect of b1- or b2-adrenergic stimulation between groups was
analyzed with two-way repeated measurements ANOVA. Post-hoc test-
ing was performed with Student’s unpaired t test. P , 0.05 was regarded
as statistically significant.
TABLE 1. Physical characteristics of subjects participating in the b1- and b2-adrenoceptor studies
b1-Adrenoceptor study b2-Adrenoceptor study
Obese (n 5 9) Lean (n 5 10) Obese (n 5 10) Lean (n 5 11)
BW (kg) 103.1 (85.6–119.1) 73.3 (57.0–82.2)a 102.3 (88.6–120.7) 73.7 (55.2–94.6)a
Ht (m) 1.78 (1.72–1.84) 1.76 (1.63–1.84) 1.76 (1.62–1.84) 1.77 (1.63–1.90)
BMI (kg/m2) 32.4 (29.1–36.0) 23.7 (20.4–26.6)a 33.2 (29.5–37.1) 23.4 (19.1–26.4)a
Body fat (%) 31.4 (24.0–36.1) 22.2 (14.0–31.0)b 31.8 (22.0–43.9) 22.1 (13.2–26.4)a
Fat-free mass (kg) 70.4 (60.7–77.8) 57.1 (39.4–68.5)b 69.5 (61.7–77.9) 57.3 (38.1–71.4)b
Age (yr) 46 (39–51) 41 (34–50)c 47 (40–50) 43 (34–50)
Values are means (range).
a P , 0.001, obese vs. lean, by unpaired t test.
b P , 0.01, obese vs. lean, by unpaired t test.
c P , 0.05, obese vs. lean, by unpaired t test.
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Results
b1-Adrenoceptor study
Baseline energy expenditure was significantly higher in
obese compared with lean men (5.49 6 0.21 vs. 4.61 6 0.18
kJ/min; P , 0.01), but after adjustment for FFM, it was
comparable between groups (obese vs. lean, 5.19 6 0.25 vs.
5.15 6 0.14 kJ/min adjusted for FFM; P 5 NS). During b1-
adrenergic stimulation, energy expenditure increased sig-
nificantly (Fig. 1). RER was similar at baseline between obese
and lean men (0.799 6 0.013 vs. 0.797 6 0.011; P 5 NS). RER
significantly decreased during b1-adrenergic stimulation.
Lipid and carbohydrate oxidations were comparable in obese
and lean subjects at baseline [lipid oxidation, 76 6 7 vs. 66 6
6 mg/min (P 5 NS); carbohydrate oxidation, 93 6 19 vs. 77 6
14 mg/min (P 5 NS)]. Lipid oxidation significantly increased
and carbohydrate oxidation significantly decreased during
b1-adrenergic stimulation. The changes in energy expendi-
ture, RER, lipid oxidation, and carbohydrate oxidation were
similar in obese and lean men (Fig. 1).
At baseline, plasma NEFA and glycerol levels were similar
in obese and lean men [NEFA, 542 6 60 vs. 409 6 46 mmol/L
(P 5 NS); glycerol, 77.7 6 8.2 vs. 62.6 6 8.6 mmol/L (P 5 NS)].
Both groups showed similar dose-related increases in plasma
NEFA and glycerol levels (Fig. 2). Baseline glucose and in-
sulin levels were significantly higher in the obese compared
with the lean group (glucose, P , 0.05; insulin, P , 0.01;
Table 2). Plasma glucose levels significantly decreased and
plasma insulin levels significantly increased during b1-
adrenergic stimulation with dobutamine. The changes in
these parameters compared with baseline were not signifi-
cantly different between groups. At baseline, plasma lactate
and potassium concentrations were similar in obese and lean
men. During b1-adrenergic stimulation, plasma lactate levels
remained similar, whereas plasma potassium levels showed
some variation, but no dose-dependent changes in either
group (Table 2).
Plasma dobutamine levels significantly increased to sim-
ilar concentrations in obese and lean men (Fig. 3). Baseline
norepinephrine and epinephrine levels were comparable be-
tween overweight and normal weight subjects (norepineph-
rine, 1.59 6 0.35 vs. 1.47 6 0.27 nmol/L; epinephrine, 0.19 6
0.04 vs. 0.22 6 0.03 nmol/L; both P 5 NS) and were signif-
icantly decreased in both groups during b1-adrenergic stim-
ulation (Fig. 3).
Baseline values for heart rate and systolic blood pressure
were not significantly different between groups (Table 3), but
diastolic blood pressure was significantly higher in obese
men (P , 0.01). Heart rate and systolic blood pressure sig-
nificantly increased, and diastolic blood pressure signifi-
cantly decreased in both groups during b1-adrenergic stim-
ulation with dobutamine. The changes in heart rate and in
systolic and diastolic blood pressure were comparable in
both groups (Table 3).
b2-Adrenoceptor study
Baseline energy expenditure was similar in obese and lean
men (5.13 6 0.16 vs. 4.97 6 0.09 kJ/min adjusted for FFM; P 5
NS). During b2-adrenergic stimulation, adjusted energy ex-
penditure significantly increased. However, the increase in
energy expenditure was significantly lower in the obese com-
FIG. 1. Changes in energy expenditure
adjusted for FFM, RER, and lipid and
carbohydrate oxidation during b1-
adrenergic stimulation with dobut-
amine in 9 obese () and 10 lean (f)
men. Values are the mean 6 SEM. ###,
P , 0.001, by ANOVA for treatment.
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pared with the lean group (ANOVA for energy expendi-
ture 3 group, P , 0.05; Fig. 4). At baseline, RER was similar
in obese and lean men (0.838 6 0.011 vs. 0.825 6 0.008; P 5
NS). RER significantly decreased during b2-adrenergic stim-
ulation, but the decrease was significantly larger in the lean
group (ANOVA for RER 3 group, P , 0.05; Fig. 4). Baseline
lipid and carbohydrate oxidation were similar in obese and
lean subjects [lipid oxidation, 55 6 6 vs. 42 6 3 mg/min (P 5
NS); carbohydrate oxidation, 143 6 17 vs. 116 6 9 mg/min
(P 5 NS)]. Lipid oxidation significantly increased during
b2-adrenergic stimulation, but this increase was significantly
higher in the lean group (ANOVA for lipid oxidation 3
group, P 5 0.05). Carbohydrate oxidation rates significantly
decreased (ANOVA for treatment, P , 0.05) during b2-
adrenergic stimulation, but did not differ significantly be-
tween groups (Fig. 4).
At baseline, plasma NEFA levels were similar in obese and
lean men (443 6 21 vs. 395 6 34 mmol/; P 5 NS; Fig. 2).
Baseline glycerol levels were significantly higher in the over-
weight compared with the normal weight group (76.5 6 4.3
vs. 61.7 6 4.8 mmol/L; P , 0.05). During b2-adrenergic stim-
ulation with salbutamol, plasma NEFA and glycerol levels
increased significantly more in the lean compared with the
obese group (ANOVA for group 3 treatment: NEFA, P ,
0.01; glycerol, P , 0.05; Fig. 2). Plasma glucose and insulin
levels were significantly higher in the obese group at baseline
(Table 4). Plasma glucose levels remained similar in the over-
weight group, but increased significantly in the normal
TABLE 2. Plasma concentrations of glucose, insulin, lactate, and potassium during b1-adrenergic stimulation with dobutamine in obese
and lean men
Parameter Group
Dobutamine (mg/kg FFMzmin) ANOVA
0 3 6 9 Group Treatment Group 3
treatment
Glucose (mmol/L) Obese 5.56 6 0.16 5.31 6 0.21 5.16 6 0.18 5.01 6 0.18 ,0.05 ,0.001 NS
Lean 5.04 6 0.15a 4.86 6 0.15 4.74 6 0.12 4.67 6 0.11
Insulin (mU/L) Obese 14.0 6 2.7 19.4 6 4.7 21.0 6 4.5 22.7 6 5.4 ,0.05 ,0.001 NS
Lean 6.1 6 0.6b 7.8 6 1.0a 9.3 6 1.2a 10.5 6 1.2a
Lactate (mmol/L) Obese 1.28 6 0.16 1.28 6 0.17 1.27 6 0.17 1.13 6 0.10 ,0.01 NS NS
Lean 0.93 6 0.14 0.83 6 0.07a 0.81 6 0.06a 0.74 6 0.03b
Potassium (mmol/L) Obese 4.22 6 0.11 4.26 6 0.09 4.17 6 0.09 4.16 6 0.08 NS ,0.05 NS
Lean 4.07 6 0.08 4.16 6 0.09 4.18 6 0.08 4.02 6 0.07
Values are the mean 6 SEM. Obese, n 5 9; lean, n 5 10.
a P , 0.05, obese vs. lean, by unpaired t test.
b P , 0.01, obese vs. lean, by unpaired t test.
FIG. 2. Changes in plasma NEFA and
glycerol concentrations during b1-
adrenergic stimulation with dobut-
amine in 9 obese () and 10 lean (f)
men (left panels) and during b2-adren-
ergic stimulation with salbutamol in
combination with atenolol in 10 obese
() and 11 lean (f) men (right panels).
Values are the mean 6 SEM. ###, P ,
0.001 (by ANOVA for treatment). *, P ,
0.05; **, P , 0.01; ***, P , 0.001 (by
unpaired t test, obese vs. lean).
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weight group during b2-adrenergic stimulation. Plasma in-
sulin levels increased significantly more in the obese com-
pared with the lean group during salbutamol infusion. Base-
line lactate and potassium concentrations were similar in
both groups. Lactate levels significantly increased, and po-
tassium levels significantly decreased during b2-adrenergic
stimulation, but remained comparable between groups (Ta-
ble 5).
Plasma salbutamol concentrations increased to a similar
level in obese and lean men during both infusion periods
TABLE 3. Heart rate and systolic and diastolic blood pressures during b1-adrenergic stimulation with dobutamine in obese and lean men
Parameter Group
Dobutamine (mg/kg FFMzmin) ANOVA
0 3 6 9 Group Treatment Group 3
treatment
Heart rate (beats/min) Obese 66 6 3 65 6 4 68 6 4 76 6 5 NS ,0.001 NS
Lean 59 6 2 59 6 2 64 6 2 77 6 5
Systolic blood pressure (mm Hg) Obese 126 6 4 140 6 6 150 6 7 157 6 6 NS ,0.001 NS
Lean 122 6 4 142 6 5 153 6 4 160 6 4
Diastolic blood pressure (mm Hg) Obese 95 6 2 89 6 3 82 6 3 80 6 3 NS ,0.001 NS
Lean 84 6 3a 80 6 3 76 6 4 75 6 5
Values are the mean 6 SEM. Obese, n 5 9; lean, n 5 10.
a P , 0.05, obese vs. lean, by unpaired t test.
FIG. 3. Changes in plasma dobutamine
(left panel) or salbutamol (right panel)
and plasma norepinephrine and epi-
nephrine concentrations during b1-
adrenergic stimulation with dobut-
amine in 9 obese () and 10 lean (f)
men (left panels) and during b2-adren-
ergic stimulation with salbutamol in
combination with atenolol in 10 obese
() and 11 lean (f) men (right panels).
Values are the mean 6 SEM. ##, P ,
0.01, ###, P , 0.001 (by ANOVA for
treatment). *, P , 0.05; **, P , 0.01 (by
unpaired t test, obese vs. lean).
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(Fig. 3). Baseline norepinephrine levels were comparable be-
tween overweight and normal weight subjects (2.57 6 0.16 vs.
2.36 6 0.16 nmol/L; P 5 NS), but baseline epinephrine levels
were significantly higher in the lean group (0.13 6 0.02 vs.
0.22 6 0.03 nmol/L; P , 0.01). Norepinephrine levels in-
creased similarly in both groups during b2-adrenergic stim-
ulation. Epinephrine levels decreased significantly in both
groups during b2-adrenergic stimulation, but the decrease
was significantly higher in the lean group (Fig. 3).
Baseline values for heart rate and systolic and diastolic
blood pressure were not significantly different between
obese and lean men (Table 5). Heart rate significantly in-
creased, systolic blood pressure remained similar, and dia-
stolic blood pressure significantly decreased in both groups
during b2-adrenergic stimulation with salbutamol. The
changes in heart rate and systolic and diastolic blood pres-
sure were similar in obese and lean men (Table 5).
Discussion
The aim of the present studies was to examine the roles of
the b1- and the b2-adrenoceptor in thermogenesis and lipid
utilization in obese and lean men. During b1-adrenergic stim-
ulation with dobutamine, no differences were found in the
changes in energy expenditure and lipid utilization between
groups. During b2-adrenergic stimulation with salbutamol,
obese subjects had a reduced increase in energy expenditure;
a reduced decrease in RER, suggesting a blunted increase in
TABLE 4. Plasma concentrations of glucose, insulin, lactate, and potassium during b2-adrenergic stimulation with salbutamol in obese
and lean men
Parameter Group
Salbutamol (ng/kg FFMzmin) ANOVA
0 50 100 Group Treatment Group 3
treatment
Glucose (mmol/L) Obese 5.64 6 0.18 5.56 6 0.17 5.67 6 0.14 ,0.01 ,0.01 ,0.05
Lean 4.89 6 0.12a 4.96 6 0.15b 5.17 6 0.15b
Insulin (mU/L) Obese 11.8 6 2.4 17.2 6 4.0 17.9 6 3.3 ,0.05 ,0.001 ,0.05
Lean 5.0 6 0.4a 6.8 6 0.8b 8.5 6 1.1b
Lactate (mmol/L) Obese 1.06 6 0.11 1.12 6 0.11 1.27 6 0.10 NS ,0.001 NS
Lean 0.86 6 0.13 0.89 6 0.08 1.03 6 0.07
Potassium (mmol/L) Obese 4.32 6 0.01 4.32 6 0.07 4.05 6 0.07 NS ,0.001 NS
Lean 4.21 6 0.07 4.29 6 0.08 4.03 6 0.08
Values are the mean 6 SEM. Obese, n 5 10; lean, n 5 11.
a P , 0.05, obese vs. lean, by unpaired t test.
b P , 0.01, obese vs. lean, by unpaired t test.
FIG. 4. Changes in energy expenditure
adjusted for FFM, RER, and lipid and
carbohydrate oxidation during b2-
adrenergic stimulation with salbuta-
mol in combination with atenolol in 10
obese () and 11 lean (f) men. Values
are the mean 6 SEM. #, P , 0.05; ##, P ,
0.01; ###, P , 0.001 (by ANOVA for
treatment). *, P , 0.05 (by unpaired t
test, obese vs. lean).
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lipid oxidation; and a reduced increase in plasma NEFA and
glycerol concentrations, suggesting a reduced lipolytic re-
sponse. Even when comparing similar increases in thermo-
genesis in the lean subjects between studies, the accompa-
nying changes in energy expenditure, RER, and plasma
NEFA and glycerol concentrations in the obese were blunted
during b2-adrenergic stimulation. This is in line with other
studies (5, 7, 19) that found similar impaired responses dur-
ing sympathetic activation in the obese.
The interpretation of the data from our study highly de-
pends on the selectivity of the b-adrenoceptor agonists used.
An earlier study from our group (9) showed that dobutamine
induced b1-adrenoceptor-specific changes in thermogenesis
and lipid utilization in dosages of 10 mg/kg BWzmin or less.
The maximum dose we used was 9 mg/kg FFMzmin, which
is comparable with 7.5 mg/kg BWzmin and thus lies within
the range of b1-adrenoceptor specificity. Our earlier study (9)
also showed that the b2-adrenoceptor agonist salbutamol in
a concentration of 85 ng/kg BWzmin (or 100 ng/kg FFMzmin)
also induced b1-adrenoceptor-specific changes in lipid uti-
lization. Addition of the b1-adrenoceptor antagonist atenolol
prevented simultaneous b1-adrenergic stimulation, but did
not affect b2-adrenoceptor-specific changes. Therefore, in the
current study salbutamol was given in combination with
atenolol to investigate b2-adrenoceptor specific changes in
thermogenesis and lipid utilization.
Our study suggests that it is the b2-adrenoceptor that is
responsible for the impaired responses in thermogenesis,
lipid oxidation, and lipolysis in the obese in vivo. In in vitro
studies, similar results are found in relation to lipolysis.
Glycerol release from sc abdominal fat cells from normal
weight and overweight women was similar after incubation
with dobutamine, but after incubation with isoprenaline or
terbutaline, glycerol release was reduced in fat cells from the
obese. This appeared to be due to a significant reduction in
cell surface density of b2-adrenoceptors, although messenger
ribonucleic acid (mRNA) levels were similar in both groups
(29). In another study, lean subjects with low isoprenaline
sensitivity, as measured by in vitro sc abdominal fat cell
lipolysis, appeared to have lower b2-adrenoceptor number
and mRNA level compared with lean subjects with high
isoprenaline sensitivity, whereas b1-adrenoceptor number
and mRNA levels were similar in both groups (30). Both
studies suggest that the b2-adrenoceptor is responsible for
the reduced b-adrenoceptor-mediated increase in lipolysis,
which is in line with our findings.
Further evidence for a role of the b2-adrenoceptor in the
etiology of obesity is provided by two recently found poly-
morphisms in the b2-adrenoceptor that are associated with
obesity. The Arg16Gly polymorphism in the b2-adrenoceptor
is associated with obesity in Japanese women (31). In a group
of Swedish women, this mutation is not associated with
obesity, but fat cells from women homozygous for Arg16
showed a 5-fold lower agonist sensitivity for b2-adrenocep-
tors than women heterozygous or homozygous for Gly16
(32). The Gln27Glu polymorphism is associated with obesity
in Japanese males and females (31, 33). Swedish women
homozygous for Glu27 had an average fat mass excess of 20
kg and approximately 50% larger fat cells than women ho-
mozygous for Gln27. However, no significant association
with changes in b2-adrenoceptor function was observed, as
assessed by in vitro fat cell lipolysis experiments (32). Obesity
in Swedish males tends to be negatively associated with the
Gln27Glu polymorphism (34). As we did not determine b2-
adrenoceptor polymorphisms, it is unknown whether the
impaired responses in thermogenesis and lipid utilization
found in our obese group are associated with one or both of
the above-mentioned polymorphisms. Until now, no asso-
ciations between polymorphisms in the b1-adrenoceptor and
obesity have been reported.
The reduced increases in thermogenesis and lipid oxida-
tion during b2-adrenergic stimulation in the obese might also
be explained by the reduced increase in NEFA in blood. The
amount of NEFA presented to skeletal muscle was therefore
reduced, which may have resulted in a smaller increase in
lipid oxidation and thermogenesis. As shown in Fig. 5, there
was a clear relationship between the increases in plasma
NEFA concentration and the increases in energy expenditure
and lipid oxidation during b1- and b2-adrenergic stimula-
tion. Furthermore, we recently reported that for a certain
increase in plasma NEFA concentration produced by lipid
heparin infusion, similar increases in thermogenesis and
lipid oxidation are found in obese and lean men (35). These
data suggest that not only b2-adrenergic stimulation but also
NEFA availability might be related to the blunted responses
in thermogenesis and lipid oxidation. Other studies reported
not only impaired responses in adipose tissue metabolism,
but also in skeletal muscle metabolism, where thermogenesis
and lipid oxidation are presumed to be predominantly lo-
calized (36). Blaak et al. (7) showed that although plasma
NEFA levels increased significantly during nonselective
b-adrenergic stimulation, no net uptake of NEFA in skeletal
muscle occurred in the obese. Moreover, others found that
obese women have a decreased capacity to oxidize substrates
TABLE 5. Heart rate and systolic and diastolic blood pressures during b2-adrenergic stimulation with salbutamol in obese and lean men
Parameter Group
Salbutamol (ng/kg FFMzmin) ANOVA
0 50 100 Group Treatment Group 3
treatment
Heart rate (beats/min) Obese 58 6 2 65 6 2 74 6 3 NS ,0.001 NS
Lean 53 6 2 59 6 2 67 6 3
Systolic blood pressure (mm Hg) Obese 121 6 4 119 6 4 122 6 5 NS NS NS
Lean 113 6 2 117 6 3 118 6 2
Diastolic blood pressure (mm Hg) Obese 90 6 4 85 6 4 83 6 4 NS ,0.001 NS
Lean 82 6 3 80 6 3 75 6 2
Values are the mean 6 SEM. Obese, n 5 10; lean, n 5 11.
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and have increased glycolytic and anaerobic capacities, as
measured by the activities of several key enzymes in skeletal
muscle biopsies (37, 38). This suggests that lipid oxidation
and thermogenesis are impaired in the obese independently
from NEFA availability. Our b1-adrenoceptor study and the
study using lipid heparin infusion (35) show that similar
increases in thermogenesis and lipid oxidation occur in obese
and lean men for a certain increase in plasma NEFA con-
centration, and therefore do not support these findings.
The reduced increase in plasma NEFA and glycerol con-
centrations and the consequent reduced increases in lipid
oxidation and thermogenesis during b2-adrenergic stimula-
tion might be explained not only by a defect in the b2-
adrenoceptor or the pathways it mediates, as stated above,
but also by the slightly higher increase in insulin concentra-
tion in the obese, because insulin inhibits lipolysis. As the
obese group was insulin resistant according to their high
baseline insulin levels, the impact of this higher increase is
difficult to interpret. Comparing the b1- with the b2-adre-
noceptor study, the increases in plasma insulin level were
almost identical between studies (obese vs. lean, b1 study,
8.7 6 3.5 vs. 4.4 6 0.8 mU/L; b2 study, 6.0 6 1.0 vs. 3.5 6 0.8
mU/L), whereas the increases in NEFA and glycerol levels,
lipid oxidation, and thermogenesis were only impaired in the
b2-adrenoceptor study. Furthermore in in vitro lipolysis tests,
b2-adrenoceptor-mediated lipolysis was reduced in fat cells
from the obese, although no insulin was present in the in-
cubation medium (29, 30). These data suggest that the im-
paired increases in plasma NEFA and glycerol concentration
were not due to the slightly higher increase in plasma insulin
concentration in the obese during b2-adrenergic stimulation.
However, as changes in insulin concentration and not in
insulin action were measured, repeating the experiment dur-
ing a hyperinsulinemic clamp can only provide direct evi-
dence for a role of insulin in the blunted responses in the
obese. Two other studies investigated the role of insulin in
epinephrine-induced thermogenesis. One study showed that
epinephrine induced energy expenditure independently
from insulin concentrations (39), whereas the other study
found an inhibitory effect of insulin (40).
Aging is also known to reduce the sensitivity for cat-
echolamines and thus for b-adrenoceptor agonists (41, 42). In
our b2-adrenoceptor study, obese and lean subjects were of
similar age, but in the b1-adrenoceptor study, the obese
group was slightly, but significantly, older than the lean one.
However, as our groups differed by only 5 yr in age, whereas
subjects in studies on the effect of aging commonly differ by
more than 30 yr of age, we believe that the difference in
catecholamine sensitivity between our subjects was only mi-
nor and therefore did not influence the interpretation of our
data.
The impaired responses to b2-adrenergic stimulation may
be caused by differences in norepinephrine kinetics. Studies
with tritiated norepinephrine have shown that norepineph-
rine appearance rates are similar (43, 44) or higher (45, 46)
and norepinephrine clearance rates are similar (17, 45, 46) or
lower (18) in subjects with a greater fat mass. This suggests
that basal sympathetic nervous system activity may be
chronically increased in the obese. As a consequence, b-
adrenoceptors may become desensitized and/or down-
regulated, resulting in reduced sympathetic nervous system
responses during additional b-adrenergic stimulation, as
shown in this and other studies (5, 7, 15, 16, 19–21). With
regard to our study, it is unclear why this desensitization
and/or down-regulation would only affect the b2-adreno-
ceptor and not the b1-adrenoceptor.
The question remains of whether the impaired responses
during b2-adrenergic stimulation are a cause or a conse-
quence of obesity. Blaak et al. (47) showed that b-adreno-
ceptor-mediated thermogenesis tended to increase after
weight loss. This suggests that the impaired sympathetic
nervous system response is a consequence of the obese state.
On the other hand, Astrup et al. (48) showed that glucose-
induced increases in energy expenditure and norepinephrine
levels improved in obese subjects after 30-kg weight loss, but
were still lower than those in control subjects. Furthermore,
Blaak et al. (47) showed that b-adrenoceptor-mediated in-
creases in arterial NEFA concentration and muscle NEFA
uptake remained impaired after weight reduction. This sug-
gests that a defective sympathetic nervous system may be a
primary factor leading to the development of obesity rather
than a secondary factor resulting from the obese state.
In conclusion, our studies suggest that b1-adrenoceptor-
mediated thermogenesis and lipid utilization are similar in
obese and lean men, but b2-adrenoceptor-mediated increases
in energy expenditure, lipid oxidation, and lipolysis are im-
paired in the obese.
FIG. 5. Relationship between mean
changes in plasma NEFA concentration
and mean changes in energy expendi-
ture and lipid oxidation per infusion pe-
riod during b1-adrenergic stimulation
with dobutamine () or b2-adrenergic
stimulation with salbutamol in combi-
nation with atenolol (E) in obese (E and
) and lean (F and ) men.
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